The breakthrough is only the beginning

I’ve spent much of my career around innovation, and one thing has become increasingly clear to me: Scientific capability is no longer the only test of progress. The harder test is whether a breakthrough can be delivered in the real world.

Life sciences is entering an extraordinary period. AI is accelerating parts of discovery, precision medicine is tailoring care to smaller patient groups, and advanced therapies are expanding what can be treated. But as the science moves forward, accountability is becoming more complicated in three distinct ways. It must now extend from discovery to delivery, from products to interconnected networks of partners and infrastructure, and beyond launch as products, data and services continue to shape outcomes over time.

This is the central challenge explored in Zurich’s recent report, Beyond 2030: The Future of Life Sciences. The question is no longer simply, “Can we make this breakthrough?” It is also, “Can we make it work safely, reliably and at scale – and who is responsible when it does not?”

From discovery to delivery: a longer route to real-world impact

A promising molecule, device or diagnostic still has a demanding journey ahead of it. Evidence must be generated, regulatory requirements met, manufacturing capacity secured, and payers and healthcare systems convinced of its value. This has always been the case, but the route has become more demanding and politically-charged.

Organizations still need excellent science, but they also need to understand which capabilities they should – or will be allowed to – build, acquire, license or share. A strong dataset, a specialist manufacturing process, access to a clinical-trial network or the ability to anticipate policy and regulatory change can determine whether an innovation progresses or stalls.

From products to partners: stronger interdependencies, wider consequences

As a result, the strength of the connections around each innovation is growing. Life sciences has always depended on specialist manufacturers, contract research organizations’, healthcare providers, regulators and logistics partners. Today those relationships are joined by cloud platforms, AI providers, connected devices and complex data environments. The network is broader, more digital and often more concentrated.

That changes how risk develops. A disruption in a single critical supplier, dataset, cloud environment or trial network can affect several programs and organizations at once. Decisions about what to own, outsource, duplicate or localize are therefore becoming as important as decisions about what to invent.

From launch to lifetime: accountability beyond approval

At the same time, healthcare is extending beyond hospitals and clinics into homes and daily life. A patient may monitor a condition through a wearable, receive guidance from an app, share data continuously and interact with software or AI-powered tools between appointments.

That creates real opportunities for more personalized, proactive and continuous care. It can also make responsibility harder to trace. When a decision or outcome is shaped by a patient, clinician, device, algorithm and platform, there may be no single point of accountability. Questions about who validated the output, who should act on it, who maintains the software and who owns the resulting data need clear answers.

The same issue continues after a product is launched. Connected products may require software updates and cybersecurity support. Outcome-based payment models may depend on evidence collected for years. Potentially curative therapies may create long-term financial and clinical commitments after a single intervention. In each case, responsibility can outlive the original transaction.

What leadership now requires

Governance is not a brake applied after innovation. Done well, it is part of how innovation reaches patients.

Across all three shifts, the underlying point is the same. Progress in life sciences will be judged not only by what becomes scientifically possible, but by whether the surrounding system can support it responsibly. That calls for leaders who can connect research and product strategy with regulation, manufacturing, healthcare delivery, finance, technology and public trust.

This is why I see resilience as a growth capability rather than simply a defensive measure. Organizations that map their critical dependencies, build flexibility into the processes that matter most and establish alternatives before they are needed are better placed to move with confidence when opportunities arise. Risk management should enable growth by making the route forward more robust.

From an insurance perspective, these are important conversations because they reveal where future dependencies, liabilities and accumulations of risk may form. They also create an opportunity to work with organizations earlier, while operating models, contracts and controls can still be shaped.

The next decade will produce remarkable science. But commercial advantage will depend on what happens around and after the breakthrough: who can prove it, produce it, finance it, deliver it and remain accountable for the results. That is where the harder work now sits, and where resilience will increasingly separate promising innovation from sustainable growth.